NIH Teaming Up With Pharma Giants For New Treatments

The National Institute of Health announced Thursday that three pharmaceutical companies will be granting them access to industry compounds in an attempt to help the Institute spearhead new research into treatments for a wide variety of conditions.

“Americans are eagerly awaiting the next generation of cures and treatments to help them live longer and healthier lives,” Health and Human ServiceTo accelerate our nation’s therapeutic development process, it is essential that we forge strong, innovative, and strategic partnerships across government, academia and industry.”

The companies include AstraZeneca, Lilly and Pfizer and the NIH says that additional companies may eventually sign on. The compounds will be supplied to the NIH’s newly formed Natonal Center for Advancing Translational Sciences.

Tags: , , ,

About TRNS Washington Desk

View all posts by TRNS Washington Desk
TRNS Washington Desk
News updates from on and around Capitol Hill.

Obama Signs Bill Banning Iranian Diplomat From U.S.

Hamid Abutalebi was involved in the 1979 hostage crisis in Iran where Americans were held for more than a year.

Homs, Syria A “Theatre Of Death And Destruction”: UN Envoy

Recent fighting in the city has cut its residents off from urgent deliveries of humanitarian aid, the opposition Syrian National Coalition said.

Crimea Will Be Ours Again: Ukraine PM

Arseniy Yatsenyuk said Ukraine is ready to fight to hold onto the annexed region, but will concentrate on working with the international community.

Review On Keystone Pipeline Delayed, Again

The delayed review of the pipeline now likely takes the issue off the table for the upcoming November elections.

White House: Antisemitic Flyers Disturbing, But Origins Unclear

White House Press Secretary Jay Carney on Friday told TRNS he wasn’t sure who was behind antisemitic flyers in eastern Ukraine.

Experts: Despite Little Progress, ‘Pivot To Asia’ Not Yet Dead

Senior Administration Officials

A talk hosted by The Brookings Institution looked at how the Obama administration can still make it’s ‘pivot to Asia’ work despite lost time.